Symprove's patented liquid technology is designed so that its four bacterial strains are live and metabolically active from the point of consumption, and remain so throughout transit.

This is a meaningful point of difference from freeze-dried formats.
Freeze-dried probiotics are dormant by design. The bacteria must rehydrate and reactivate before they can begin functioning, a process that competes with the transit time.

Small Gastric acid is the primary barrier standing between an oral probiotic and clinical relevance. Symprove's approach to overcoming it is built into the manufacturing process.

• Fermentation builds acid resistance:
  During production, as Symprove's bacteria grow and multiply, they generate increasing quantities of lactic acid. This shifts the local environmental conditions and upregulates genes encoding proton pumps, increasing the number of proton pumps incorporated into the bacterial cell membrane. The result is a bacterium better equipped to export protons, maintain intracellular pH, and withstand acidic conditions before it ever reaches the patient.
• Transit is fast: As a small-volume liquid bolus, Symprove is shown to pass through the stomach in under 10 minutes when taken in the fasted state (Fredua-Agyeman, 2015), limiting the window of acid exposure by design.
• The outcome is measurable: Independent research shows that 99.3% of Symprove's bacteria survive gastric transit and reach the colon alive (Moens, 2019).

Microbial effects

• Increase in bacterial diversity within gut microbiome (Moens 2019)
• SCFAs (acetate, propionate, butyrate) and lactate produced by Symprove bacteria within 6 hours (Ghyselinck 2020) which starts cross-feeding with good commensal bacteria in the gut microbiome
• Butyrate production supports gut wall integrity through positive impact on tight junctions between epithelial cells (Ghyselinck 2020, Ghyselinck 2021)

Anti-pathogen effect:

• Change in local pH and production of
  bacteriocides may help suppress gut pathogens (Hatton 2026, Fredua-Agyeman 2017, Dodoo 2019, Dodoo 2025)

Anti-inflammatory effect:

• Reducing pro-inflammatory markers, e.g. TNF-α, MCP-1, CXCL-10, IL-8 (Moens 2019, Ghyselinck 2020)
• Increase anti-inflammatory markers, e.g. IL-6, IL-10 (Moens 2019, Ghyselinck 2020)

For patients, gut symptoms are rarely just physical, they shape routine, confidence and quality of life.

For clinicians, the case for any probiotic recommendation should rest on a coherent, evidenced explanation of how the specific probiotic is designed to work, not on category assumptions.

Symprove's mechanistic of action offers exactly. From acid resistance built during the fermentation process, rapid gastric transit, measured colonic survival, and downstream microbial, anti-pathogenic and anti-inflammatory effects, that can be explained to a patient.

The mode of action doesn't sit in isolation. Symprove has been researched for over a decade, with 20+ published studies on the final end-product. This includes *in vitro* mechanistic work alongside independent in vivo studies in collaboration with UCL, King's College London and Sheffield Hallam University, spanning clinical populations including IBS, IBD, Parkinson's disease and long COVID.

That distinction matters clinically: findings generated on the end-product are more directly relevant to what you're recommending than strain-level data extrapolated from elsewhere.